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ABSTRACT
To gain more insight in the mechanism of action of inhibin, we
studied the effect of inhibin on activin signaling in Chinese hamster
ovary cells. Inhibin specifically counteracted activin-induced expres-
sion of a plasminogen activator inhibitor 1 promoter element (3TP)
and of the junB gene, but was ineffective when the responses were
induced by transforming growth factor-b. This indicates that inhibin
acts only on the activin-specific part of these signaling cascades.
Using a constitutively active activin type IB receptor we determined
whether inhibin acted at the level of the activin-receptor complex or
downstream of it. The mutant activin receptor stimulated the ex-
pression of the 3TP promoter in the absence of activin. This stimu-
lation was insensitive to inhibin, indicating that inhibin acts exclu-
sively at or upstream of this activin type I receptor. In addition,
competition studies using labeled activin showed that inhibin dis-
placed activin from the activin type II receptors, especially from the
activin type IIB receptor, but not from the type I receptors. In con-
clusion, these data show that in Chinese hamster ovary cells inhibin
acts directly at the activin receptor complex, most likely through
displacement of activin from the activin type II receptor. (Endocri-
nology 138: 2928–2936, 1997)
INHIBIN AND activin were originally defined as gonadalhormones regulating the release of FSH from the anterior
pituitary gland (1–3). Today, these factors are known to play
additional local roles in the gonads (4) as well as in extrago-
nadal tissues, such as in erythrocyte differentiation (5), me-
soderm induction (6, 7), apoptosis of liver parenchyme (8),
and extracellular matrix formation (9). Further, they modu-
late the growth of a number of different cell types and cell
lines (10–13). In many cell types, inhibin counteracts re-
sponses to activin; in some cases, however, inhibin is inef-
fective (11, 14, 15).
Activin and inhibin are both members of the transforming
growth factor-b (TGFb) superfamily of growth and differ-
entiation factors. Members of this family consist of two iden-
tical or highly homologous subunits, linked by one disulfide
bridge (16, 17). Activin is consistent with this model; it is a
dimer of two inhibin b-subunits. Inhibin is the only exception
in this family, as it consists of an inhibin b-subunit, which is
also present in activin, linked to a distantly related inhibin
a-subunit. Furthermore, no homodimers of the a-subunit of
inhibin have been described.
Members of the TGFb superfamily exert their actions
through combinations of type I (55 kDa) and type II (68 kDa)
receptors. Both receptors are characterized by a small extra-
cellular ligand-binding domain, a single transmembrane do-
main, and an intracellular Ser/Thr-specific kinase domain.
For both TGFb and activin, the type II receptor is a consti-
tutively active kinase that has high affinity for the ligand.
This ligand type II receptor complex subsequently interacts
with the type I receptor (18, 19). After association, the type
I receptor is phosphorylated by the kinase domain of the type
II receptor in its juxta-membrane region, also known as the
GS box (18–20). The phosphorylation of the GS box appar-
ently leads to activation of the type I receptor, resulting in
stimulation of downstream pathways.
Two activin type II receptors (ActRIIA and ActRIIB) and
two activin type I receptors (ActRIA and ActRIB, also known
as ALK-2 and ALK-4, respectively) are known (21–24). How-
ever, inhibin receptors have not been identified to date, and
the mechanism of action of inhibin has not been clarified. It
might be that inhibin signals through its own type I and type
II receptors. Alternatively, the special position of inhibin in
the TGFb superfamily may indicate that its signaling mech-
anism is different, as is also suggested by the fact that inhibin
appears to interfere specifically with activin signaling. We
investigated whether inhibin blocks activin signal transduc-
tion downstream of the activin-receptor complex or inter-
feres with activin signaling at the level of the activin receptor
as suggested earlier (13, 25). As a model, the Chinese hamster
ovary (CHO) cell line K1 was used; its cell growth is sensitive
to both activin and inhibin (11). In these cells the interference
of inhibin with activin-induced immediate early responses
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and the effect of inhibin on the activin receptor complex were
studied. This showed that inhibin acts directly at the level of
the activin-receptor complex in CHO cells. In addition, our
data indicate that inhibin can interfere with activin signaling
through displacement of activin from the activin type II
receptor.
Materials and Methods
DNA constructs
The mouse ActRIA, -IB, -IIA, -IIB2, and -IIB4 clones used were pre-
viously described (21, 24, 26) (Miyazono, K., unpublished observations).
The ActRIs used were not modified, whereas the ActRIIA and the
ActRIIBs were extended by the addition of an HA tag (27) and a KT3 tag
(28), respectively, at their 39-end as previously described (29). The ex-
pression of all constructs was under control of the human b-actin pro-
moter (30). The p3TP-Lux construct used was described previously (31).
The p5T-Lux construct was obtained by replacing the chloramphenicol
acetyltransferase (CAT) gene in pTRE-TATA-CAT (32) using XhoI and
StyI with the luciferase gene of the pGL2-basic-Lux vector (Promega
Corp., Madison, WI). The human ActRIB (23) was used as a template for
PCR mutagenesis to introduce a GAT (Asp) codon instead of a ACC
(Thr) codon at position 206 from the start codon. Both wild-type and
mutated receptors were introduced in the expression plasmid pcDNA3
(Invitrogen, Leek, The Netherlands).
Transfection and luciferase assay
CHO K1 cells were maintained in DMEM-Ham’s F-12 (DF; Life Tech-
nologies, Gaithersburg, MD) supplemented with 10% FCS (SEBAK, Aid-
enbach, Germany) and cultured at 37 C in 5% CO2 in air. Cells were
plated before transfection in 12-well plates (Costar, Cambridge, MA) at
a concentration of 4 3 104 cells/well. The next day the cells were
transiently transfected with either p3TP-Lux or p5T-Lux (0.5 mg/well)
using the calcium phosphate transfection method (33). In case of co-
transfection with activin receptor expression plasmid, up to 1.0 mg of this
plasmid was used per well. To correct for transfection efficiencies, the
b-galactosidase expression plasmid pCH110 (0.5 mg/well) (34) was
added. At 50% confluence, cells were deprived of serum and cultured
in DF containing 0.1% BSA for at least 8 h. Subsequently, the cells were
incubated with vehicle, human recombinant activin A (Innogenetics,
Ghent, Belgium), human recombinant inhibin A (Genentech, South San
Francisco, CA), TGFb (Sanbio, Breda, The Netherlands), b-phorbol 12-
myristate 13-acetate (PMA; Sigma Chemical Co., St. Louis, MO), or
steroid-free bovine ovarian follicular fluid as indicated. After 16 h, the
cells were lysed, and luciferase and b-galactosidase activities were mea-
sured (35, 36).
Northern blot analysis of junB messenger RNA (mRNA)
Serum-deprived cells were treated as described and harvested 0, 0.5,
1.5, or 6 h after the addition of activin or activin and inhibin. Total RNA
was extracted by the TRIzol procedure (Life Technologies), and 20 mg
of this were fractionated on a denaturing agarose gel and then trans-
ferred to a nylon membrane (Hybond N1, Amersham, ’s-Hertogen-
bosch, The Netherlands) (37). The junB mRNA was detected using
mouse junB complementary DNA (cDNA; p465.20) as a probe (38).
Hybridization with a glyceraldehyde-3-phosphate dehydrogenase
cDNA served as a measure of the amount of RNA applied to each lane.
The labeled probe bound to the blot was quantified using a Phospho-
rImager and the ImageQuant software package (version 3.3, Molecular
Dynamics/B&L Systems, Zoetermeer, The Netherlands).
Reverse transcriptase-PCR (RT-PCR)
RT-PCR was performed on total RNA of CHO cells and K562 cells as
previously described (39) using the oligonucleotide primers described
below. As a control, PCR was performed on cDNA clones of the mouse
ActRIIA, ActRIIB2, and ActRIIB4 described above. For ActRIIA, primers
derived from the rat cDNA sequence (40) were used for the amplification
(forward primer, 59-CAGGGAACTG GATATCTAGA GAGAACTTC-
39; reverse primer, 59-TGGTCCTGGG TCTCGAGTAG GAACAAG-
TAC-39); for ActRIIB, primers derived from the human ActRIIB (41) were
used (forward primer, 59-CGAATTCCGC TGCTGCCCAT TGGAGGC-
39; reverse primer, 59-TGTAAGCTTG TGGCCCTCAC CACGACACC-
39). The ActRIIA primers amplify a fragment of 685 bp; the ActRIIB
primers amplify a 790-bp fragment for the ActRIIB2 and a 766-bp frag-
ment for the ActRIIB4. The PCR reaction consisted of 40 cycles of de-
naturation at 94 C for 1 min, primer annealing at 50 C for 2 min, and
subsequent extension reaction at 72 C for 2 min using 0.2 U SuperTaq
(HT/Biotechnology, Cambridge, UK). Reaction products were analyzed
by agarose (2%) gel electrophoresis and visualized by ethidium bromide
staining.
Cross-linking
COS-1 cells were maintained in DF supplemented with 7.5% FCS and
cultured at 37 C in 5% CO2 in air. Wild-type CHO cells or activin
receptor-transfected COS cells (;2–4 3 106 cells) were preincubated for
30 min at 4 C without additions or with unlabeled activin A or inhibin
A followed by an incubation of 2 h at 4 C with 10 ng [125I]activin A (180
pm; ;750,000 cpm) in 2 ml DF. Activin A was iodinated using chlora-
mine-T as previously described (29). After the incubation, the cells were
washed twice with HEPES-buffered saline. Bound activin was cross-
linked to its receptor with 1 mm bis-sulfosuccinimidyl suberate (BS3,
Pierce Chemical Co., Rockford, IL) as described previously (29). Sub-
sequently, the cells were lysed, and the cross-linked complexes were
purified. For CHO cells, this was achieved by incubating the extracts
with wheat-germ agglutinin agarose overnight; for activin receptor-
transfected COS-1 cells, the complexes were first incubated overnight
with specific antibodies to either the HA or the KT3 tag present on the
C-terminus of the ActRII. The resulting complexes were subsequently
isolated by an incubation with either protein A- or protein G-Sepharose,
as previously described (29), and subsequently separated on a reducing
SDS-PAGE followed by autoradiography. The amount of iodinated ac-
tivin cross-linked to either activin receptor was quantified using a Phos-
phorImager and the ImageQuant software package.
Results
Inhibin blocks expression of immediate early genes induced
by activin
To study the mechanism of action of inhibin in CHO cells,
we initially determined whether inhibin was able to affect
activin-induced immediate early expression of the junB gene
and the commonly-used artificial 3TP-Lux reporter gene. The
3TP-Lux reporter construct contains a TGFb/activin respon-
sive region of the plasminogen activator inhibitor 1 (PAI-1)
promoter and three 12-O-tetradecanoylphorbol acetate
(TPA)-responsive elements (TREs) (31). Activin (0.9 nm; ED50
5 180 pm) stimulated the luciferase activity in CHO cells
transfected with the 3TP-Lux reporter construct 6-to 8-fold.
The luciferase activity was already detectable after 4 h, but
was maximal between 16–24 h after the start of the incuba-
tion (not shown). Inhibin on its own did not elicit a response,
but it reduced the response to activin dose-dependently (Fig.
1, A and C). To investigate whether this activin-induced
response was specifically affected by inhibin, we also studied
the effect of inhibin on TGFb-induced 3TP reporter activity.
TGFb was chosen because it is known to induce similar
responses as activin, including 3TP reporter activity, in a
number of cell types (11, 42, 43). TGFb (150 pm; ED50 5 25
pm) stimulated luciferase activity in the 3TP-Lux construct 8-
to 10-fold (Fig. 1A; dose-response curves not shown). This
TGFb-induced luciferase activity, however, was insensitive
to inhibition by inhibin (Fig. 1A). Even a relatively high doses
of inhibin (2 nm) was completely ineffective (not shown).
Activin and TGFb both act through either one of the two
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different response elements in the 3TP promoter. Therefore,
we studied the effect of activin, TGFb, and the protein kinase
C activator, PMA, on a reporter construct containing just
TREs, p5T-Lux. PMA (50 nm) stimulated the reporter activity
of this construct in CHO cells 3-fold, whereas activin (1 nm)
and TGFb (250 pm) had no effect (Fig. 1B). In addition, we
found that the effects of TGFb and PMA on the 3TP-Lux
construct were additive (not shown). Thus, the transcription
from the 3TP promoter induced by both activin and TGFb is
likely to be exclusively derived from the PAI-1 promoter
element in the 3TP-Lux construct. As inhibin only interferes
with the activin-induced 3TP promoter activation, inhibin
exerts its effect on a part of the activin signaling cascade that
is not in common with that of TGFb.
In addition, we studied whether expression of an unre-
lated activin-inducible immediate early gene, junB, was also
sensitive to inhibin. To this end, CHO cells were treated with
activin in the absence or presence of inhibin. Activin induced
junB mRNA levels 4-fold within 30 min, but the response
rapidly declined thereafter (Fig. 2). Inhibin reduced the ac-
tivin-dependent junB expression significantly (P , 0.005, by
Mann-Whitney U test). Equimolar amounts of inhibin re-
duced activin-induced junB expression by 28 6 4.1% and
reduced activin-induced 3TP luciferase activity by 27 6 7%.
This indicates that both immediately early responses to ac-
tivin are equally sensitive to inhibin. On a molar basis, how-
ever, inhibin is less effective than activin.
Inhibin competes with activin at the activin-receptor
complex in COS-1 and CHO cells
Experiments reported by Carcamo and co-workers (42)
suggested that the pathways for 3TP promoter activation,
PAI-1 expression, and growth inhibition downstream of the
type I receptors for TGFb and activin are identical. Because
inhibin did not interfere with the effects of TGFb, this implies
that the activin-receptor complex itself is the primary target
for inhibin action in CHO cells. We, therefore, studied
whether inhibin was able to displace activin from the activin-
receptor complex. Previous work showed that inhibin, al-
though with low potency, is able to displace activin from the
ActRIIs (21, 24, 25). These experiments, however, were per-
formed on cells expressing type II receptors but no type I
receptors. We included the two ActRIs in our analysis be-
FIG. 1. Inhibin inhibits activin-dependent 3TP promoter activity.
Relative luciferase activity was determined in CHO cells that were
transiently transfected with either p3TP-Lux (A and C) or p5T-Lux
(B). Transfected cells deprived of serum were stimulated for 16 h with
vehicle (C), activin (A; 900 pM), TGFb (T; 150 pM), inhibin (I; 900 pM),
or PMA (P; 100 nM), alone or, when indicated, in combination with
inhibin (900 pM). For the dose-response curve for inhibin (C), cells
were treated with activin (900 pM) in combination with the indicated
concentrations of inhibin. Luciferase activity was measured in cell
lysates and is plotted as the mean 6 SEM (n 5 6). Data were subjected
to one-way ANOVA according to Scheffe. *, Significantly different
from control cells (P , 0.05); **, significantly different from control
and activin-treated cells (P , 0.05); E, significantly different from
control, but not different from TGFb-treated cells (P , 0.05). The
results of one experiment of three with similar results are shown.
FIG. 2. Induction of junB mRNA expression in CHO cells by activin
and inhibin. The junB mRNA expression was determined by Northern
blot analysis in CHO cells treated for 0, 0.5, 1.5, and 6 h with activin
(900 pM) or with activin in combination with inhibin (800 pM). A,
Autoradiograph of the Northern blot. The size of the mRNA is indi-
cated on the left. B, Quantification (see Materials and Methods) of
junB mRNA levels. The junB mRNA/glyceraldehyde-3-phosphate de-
hydrogenase mRNA levels are plotted against the duration of the
incubation. The mean 6 SD of two independent experiments are
shown. The junB mRNA time curve of cells treated with activin is
significantly different from that of cells treated with activin and
inhibin (by Mann-Whitney U test, P , 0.005).
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cause they are an essential part of the activin signaling com-
plex (18, 19) and could also be targets for inhibin or required
for inhibin action. Using transient transfection, different sets
of ActRI and ActRII cDNAs were introduced into COS-1
cells. COS-1 cells were used because these cells do not ex-
press endogenous activin receptors that might interfere with
the assay (21). The transfected cells were incubated with
unlabeled activin (0.6 or 1.8 nm), unlabeled inhibin (2.3 or 7
nm), or vehicle to allow ligand binding. Subsequently, io-
dinated activin (0.18 nm) was added, and the incubation was
continued for 2 h. Bound hormone was cross-linked to the
receptors, immunoprecipitated with an antibody to the
tagged ActRII, and subsequently analyzed by SDS-PAGE
under reducing conditions. The results of ActRIB in combi-
nation with ActRIIA or with the most common splice variant
of ActRIIB, ActRIIB2 (24, 41), are shown (Fig. 3A). Experi-
ments with another splice variant of ActRIIB, ActRIIB4, were
also performed. This splice variant differs from the ActRIIB2
in a small part of the extracellular domain that affects the
affinity for activin (24). The results obtained with ActRIIB4
were comparable to those obtained with ActRIIB2 (not
shown). In addition, ActRIA was tested in combination with
all three type II receptors. The results obtained with this
receptor were identical to those with ActRIB (not shown).
Iodinated activin subunits were predominantly cross-
linked to the ActRI and ActRII, resulting in complexes of
65 and 85 kDa in size, respectively (Fig. 3A, control lanes).
In addition, some minor larger complexes (100 –160 kDa)
FIG. 3. Inhibin competes with activin
for binding to the activin-receptor com-
plex. Wild-type CHO cells (B and D) or
COS-1 cells, cotransfected with ActRIB
and the indicated ActRII cDNA expres-
sion vectors (A and C), were affinity la-
beled by incubation with iodinated ac-
tivin alone (control) or in the presence of
unlabeled activin (Act) or inhibin (Inh).
After cross-linking with bis-sulfosuc-
cinimidyl suberate, the cells were lysed,
and the receptor complexes were immu-
noprecipitated using antibodies against
the tags of the different ActRIIs or, in
case of CHO cells, with wheat-germ ag-
glutinin agarose. Precipitates were sub-
jected to SDS-PAGE under reducing
conditions, followed by autoradiogra-
phy. The autoradiographs are shown in
A and B. The amount of labeled activin
cross-linked to the ActRI and ActRII
was quantified using a PhosphorIm-
ager and plotted against the dose of un-
labeled activin or inhibin added (C and
D). The results of a representative ex-
periment are shown; essentially similar
results were obtained in three indepen-
dent experiments.
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were observed, presumably consisting of multiple activin
subunits and/or activin receptors cross-linked to each
other (13).
Preincubation with unlabeled activin resulted in a gradual
decrease in the amount of labeled activin cross-linked to the
ActRI and ActRII (Fig. 3A). The ratio of the amount of labeled
activin cross-linked to the ActRI over that cross-linked to
ActRII decreased (to 35 6 9% and 40% 6 6% for ActRIIA and
ActRIIB2, respectively) relative to the ratio in the absence of
competitor (P , 0.05, by Student’s t test; n 5 3; Fig. 3C). In
the presence of inhibin, the amounts of labeled activin cross-
linked to both ActRII and ActRI also decreased (Fig. 3A).
However, the ratio between the amount of labeled activin
cross-linked to the ActRI and that cross-linked to ActRII did
not change significantly after the addition of inhibin (99 6 6%
and 107% 6 20% for ActRIIA and ActRIIB2, respectively)
compared to that in the absence of competitor (Fig. 3C). This
difference between activin and inhibin was observed for all
ActRI and ActRII combinations tested. In the presence of
unlabeled inhibin, labeled activin was cross-linked more ef-
ficiently to ActRIIA than to ActRIIB2; inhibin was approxi-
mately 15 times less potent than activin in competing for
labeled activin bound to ActRIIA, whereas this difference for
ActRIIB2 was only 2.5. This difference was independent of
the type I receptor (IA or IB) transfected into COS-1 cells. This
set of experiments indicates that ActRIIs, but not ActRIs, can
be targets for inhibin and that inhibin preferentially interacts
with ActRIIBs.
In addition, we performed similar displacement studies
with the endogenous activin receptors of CHO cells that were
incubated with labeled activin (0.18 nm) alone or in the pres-
ence of unlabeled activin (3.6 nm) or inhibin (3.0 nm). After
cross-linking, the complexes were purified by binding to
wheat-germ agglutinin agarose beads and analyzed on SDS-
PAGE (Fig. 3B). Similar to the results of the COS-1 cell ex-
periments, labeled activin was predominantly cross-linked
to a type I and a type II receptor and unlabeled activin and
inhibin reduced the amount of labeled activin cross-linked to
both type I and type II receptors (Fig. 3B). However, unlike
the findings in COS-1 cells, unlabeled activin did not affect
the ratio of labeled activin cross-linked to ActRI and ActRII
(Fig. 3, B and D). Inhibin was 2–3 times less potent than
unlabeled activin in displacing labeled activin from the en-
dogenous ActRII in CHO cells (Fig. 3D).
To identify the ActRIIs involved in this binding, we
analyzed which of the known ActRIIs are expressed in
CHO cells. Expression levels of ActRIIs were too low to be
detected on a Northern blot. Therefore, we identified the
receptors by PCR using primers specific for either ActRIIA
(Fig. 4A) or ActRIIB (Fig. 4B). Both receptors were detected
in CHO cells; the only ActRIIB splice variant present was
ActRIIB2. Another inhibin-responsive cell line, K562,
which predominantly expresses ActRIIB2, as determined
by ribonuclease protection (van Schaik, R. H. N., unpub-
lished results) was included in this analysis as a control.
In these cells, ActRIIB2 could be amplified to a prominent
band (Fig. 4B, lane 7), whereas no ActRIIA could be de-
tected in these cells.
Inhibin is unable to block the response from a constitutively
active ActRIB
To exclude a role for inhibin in the activin signal trans-
duction pathway downstream of the receptor complex, the
ability of inhibin to inhibit the induction of 3TP-Lux reporter
activity by a constitutively active ActRIB receptor was in-
vestigated. In analogy with the constitutively active TGFb
type I receptor (TGFbRI) (44), we replaced threonine 206
located between the GS box and the kinase domain by as-
partate in the ActRIB (T206D). The ActRIB was chosen be-
cause ActRIB and not ActRIA mediates PAI-1 expression and
growth inhibition by activin in Mv1Lu cells (42), and ActRIB
mediates 3TP promoter activation by activin in CHO cells
(45). To ascertain the constitutive activity of this mutant
receptor, we compared 3TP promoter activation in the ab-
sence of activin in CHO cells transfected with increasing
amounts of wild-type or mutant ActRIB expression plasmid
(Fig. 5A). In cells transfected with the wild-type receptor
construct, luciferase activity was low and did not depend on
the amount of expression plasmid. In contrast, the luciferase
activity considerably increased with increasing amounts of
expression plasmid when the mutant ActRIB was intro-
duced. This indicates that the replacement of threonine 206
by aspartate leads to the activation of the ActRIB in the
absence of activin, as was also recently shown by Attisano et
al. (18). The constitutively active receptor did not activate the
5T-Lux construct containing only TREs (Fig. 5B), showing
that 3TP promoter activation by this mutant receptor is pro-
moter specific and is not due to aspecific changes due to, for
example, overexpression of this receptor. Subsequently,
CHO cells were transfected with either wild-type ActRIB or
FIG. 4. ActRIIA and ActRIIB2 are expressed in CHO cells. RT-PCR
of total RNA was performed to identify ActRIIA (A) and ActRIIB (B)
in CHO and K562 cells. The PCR products were subsequently ana-
lyzed on a 2% agarose gel. A, Detection of ActRIIA mRNA: pBR322
digested with HinfI and EcoRI (lane 1); control PCR (lane 2); PCR of
cDNA clone of mouse ActRIIA (lane 3); RT-PCR of total RNA of CHO
cells (lane 4, with RT; lane 5, without RT); RT-PCR of total RNA of
K562 cells (lane 6, with RT; lane 7, without RT). B, Detection of
ActRIIB mRNA: pBR322 digested with HinfI and EcoRI (lane 1); PCR
control (lane 2); PCR of cDNA clone of mouse ActRIIB2 (lane 3) and
of mouse ActRIIB4 (lane 4); RT-PCR of total RNA of CHO cells (lane
5, with RT; lane 6, without RT); RT-PCR of total RNA of K562 cells
(lane 7, with RT; lane 8, without RT). The results of one representative
experiment of two are shown.
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ActRIB(T206D), and 3TP promoter activation was studied in
response to activin and/or inhibin (Fig. 5C). CHO cells trans-
fected with the wild-type ActRIB responded to activin with
a 4- to 5-fold increase in luciferase activity, and this activin-
dependent luciferase activity was sensitive to inhibin, similar
to that in wild-type CHO cells. In CHO cells transfected with
the mutant ActRIB, basal luciferase activity was increased
about 10-fold compared to that in cells transfected with the
wild-type ActRIB. Activin did not further increase luciferase
activity in these cells, suggesting that this mutant receptor
was already fully active in the absence of activin. More im-
portantly, the addition of inhibin (0.8 nm) was also without
effect (Fig. 5C). Even a high concentration of inhibin (2 nm)
or bovine follicular fluid containing 10 nm bioactive inhibin
did not decrease 3TP promoter activity (not shown). This
experiment shows that inhibin is unable to block 3TP pro-
moter activation induced by activin downstream of the
ActRIB in CHO cells.
Discussion
Inhibin is an endocrine and paracrine inhibitor of locally
induced activin responses in both the pituitary gland (2, 3)
and the gonads (4). However, the exact mechanism by which
inhibin affects activin-dependent responses is not clearly
understood. Here, we show that inhibin interferes with the
activin-specific part of the signaling cascade for 3TP pro-
moter activation, whereas it does not interfere with TGFb
signaling. Identical results were obtained by Gonzalez-Man-
chon and Vale using growth inhibition of CHO cells as a
parameter (11). As the signaling pathways activated by ac-
tivin and TGFb for both of these responses are nearly iden-
tical (42), this suggests that the activin-receptor complex is
the primary target for inhibin action. We have confirmed the
latter hypothesis by showing that inhibin is unable to sup-
press 3TP promoter activity induced by a constitutively ac-
tive activin type IB receptor. In addition, we demonstrated
that inhibin can displace labeled activin from the ActRII in
activin-receptor-transfected COS cells and in wild-type CHO
cells. The potency of inhibin is 6–30% that of activin de-
pending on the type II receptor present. This is in accordance
with the smaller effect of inhibin, compared to activin, on
3TP-Lux reporter and junB gene expression in these cells.
Thus, the biological effects of inhibin in CHO cells can be
explained on the basis of displacement of activin from the
ActRII, as postulated by Xu et al. (13). This argues against the
existence of a separate inhibin receptor pathway in CHO
cells. However, this does not completely exclude the possi-
bility that inhibin, via a separate inhibin receptor pathway,
interferes with activin signaling at the level of the activin-
receptor complex, e.g. via homologs of TRIP-1 that specifi-
cally interact with type II receptors (46).
Our results indicate that inhibin cannot interact with ActRI
directly or after it has formed a complex with the ActRII. This
in contrast to activin, which can interact with the ActRI after
it is complexed to a ActRII. Two observations support this
conclusion. Firstly, if inhibin interacts with the ActRI di-
rectly, it would displace labeled activin from the ActRI and
not from ActRII. This is clearly not the case, because the ratio
of labeled activin cross-linked to ActRI compared to that
FIG. 5. Inhibin acts upstream of the activin type IB receptor. A,
Mutant ActRIB (T206D) is constitutively active. The luciferase ac-
tivity of transfected CHO cells was determined as described in Fig. 1.
CHO cells were cotransfected with the p3TP-Lux reporter plasmid, a
b-galactosidase expression construct pCH110, and increasing
amounts (nanograms per well) of wild-type or mutant ActRIB recep-
tor (T206D) expression vector. b-Galactosidase was measured to cor-
rect for transfection efficiency. B, ActRIB activates the PAI-1 pro-
moter element in the 3TP promoter and not the TREs. CHO cells were
cotransfected with the p3TP-Lux or the p5T-Lux reporter plasmid in
combination with wild-type receptor (open bar) or ActRIB-T206D
(closed bar), and luciferase activity was determined as described
above. C, Inhibin does not inhibit ActRIB(T206D)-induced 3TP pro-
moter activation. Cells were cotransfected with p3TP-Lux and
pCH110 in combination with either wild-type or mutant ActRIB
(T206D; 100 ng/well). Wild-type ActRIB-transfected cells were incu-
bated with vehicle (C), activin (A; 900 pM) alone, or activin in com-
bination with inhibin (I; 900 pM); ActRIB-T206D-transfected cells
were incubated with similar doses of activin and inhibin. Relative
luciferase activity was determined in cell lysates and is plotted as the
mean 6 SEM (n 5 6). Data were subjected to one-way ANOVA ac-
cording to Scheffe. *, Significantly different from wild-type ActRIB-
transfected control cells (P , 0.05); **, significantly different from
activin-treated wild-type ActRIB-transfected control cells (P , 0.05);
E, not different from ActRIB-T206D-transfected control cells (P .
0.05). The results of one experiment of three with similar results are
shown.
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cross-linked to ActRII does not change (in either CHO or
COS-1 cells) in the presence of unlabeled inhibin compared
to the ratio in the absence of competitor. Thus, displacement
of labeled activin from ActRI by inhibin is indirect and is due
to displacement of labeled activin from ActRII, which is in
line with previous observations (13, 21, 24, 25). Secondly, we
observed that unlabeled inhibin behaves differently from
unlabeled activin in COS-1 cells overexpressing ActRs. This
phenomenon can only be explained if inhibin that is bound
to ActRIIs is unable to interact with ActRI and if an excess
of ActRIIs over ActRIs is present in transfected COS-1 cells.
In that case, unlabeled activin binds to both receptors in a
ternary complex, leaving predominantly unoccupied type II
receptors for the binding of labeled activin. In this way ac-
tivin affects the ratio of labeled activin cross-linked to ActRI
and ActRII. In the presence of unlabeled inhibin, however, no
ternary complex is formed between inhibin complexed to
ActRII and the type I receptors. Thus, the type I receptors are
not occupied, making it possible that labeled activin can bind
equally well to type I and type II receptors, as is the case in
the absence of inhibin. CHO cells may have no excess of type
II receptors, causing a similar suppression of labeled activin
bound to both types of activin receptors by activin and
inhibin.
The fact that inhibin cannot interact with the ActRI is in
line with studies performed by Xu and co-workers (13). They
showed that inhibin only interacts via its b-subunit with
ActRII and that the inhibin a-subunit cannot interact with
any ActR. This suggests that the a-subunit of inhibin has lost
domains that are important for activin receptor interaction
and that the a-subunit only prevents receptor dimerization.
This is further supported by the fact that cleavage of the
inhibin a-subunit to its mature form is not required for in-
hibin action, whereas cleavage of the inhibin b-subunit is a
prerequisite for activin action (47). In addition, compared to
the b-subunit gene, the a-subunit displays much greater
genetic variability between species (Table 1). All of these
features indicate the separate position of inhibin in the TGFb
superfamily and support its unique mechanism of action.
The displacement studies further show that ActRIIB is a
better target for competition with inhibin than is ActRIIA.
This is in line with previous observations by Mathews et al.
(21) and Attisano et al. (24). However, in contrast to results
observed by Attisano (24), our data indicate that inhibin is
almost as potent as activin in displacing labeled activin from
ActRIIB2. This may be due to the presence of a type I receptor
in our experiments. Recently, Xu and co-workers reported
that inhibin was almost as effective as activin in displacing
labeled activin from ActRIIA (13). We do not have an ex-
planation for this discrepancy with our present data; the
results of competition experiments may depend on the con-
ditions and cell type used and on the expression levels of the
ActRs. Unfortunately, Xu et al. (13) did not include ActRIIB
in their study, so a direct comparison with our data cannot
be made. In general, however, the data reported by us and
others show that inhibin can displace activin from ActRIIs
(13, 21, 24, 25), but not from ActRIs (13).
This competition model allows for a complex and intricate
regulation of target cell activities, depending on the relative
production of a- and b-subunits and the relative expression
of ActRIIA and ActRIIB2/4. Unfortunately, we were unable
to determine the ActRIIA/ActRIIB mRNA ratio for CHO
cells due to the low level of expression of both ActRIIs.
However, the human erythroid cell line K562, which is highly
sensitive to inhibin (5), shows a high ActRIIB2/ActRIIA ratio
(van Schaik, R. H. N., unpublished results), which is in line
with the idea that the ActRIIB is the ActRII that is most
sensitive to inhibin.
The current competition model can explain most data on
inhibin action. However, it is difficult to envisage how both
inhibin and activin can inhibit a response in the same cell (48,
49) and how inhibin can stimulate a response in the pre-
sumed absence of endogenous activin (50). Further, complete
insensitivity to inhibin in cells that are responsive to activin
(11, 14, 15) may be explained if these cells express the inhibin-
insensitive ActRIIA or, alternatively, if they express high
levels of ActRIIs so that physiological concentrations of in-
hibin cannot displace activin. However, it may be necessary
to postulate a separate inhibin receptor pathway to explain
all of these observations.
The similarity of the intracellular domains of ActRIB and
TGFbRI suggests that the activation of these receptors by
type II receptors and the signaling pathway downstream of
these receptors are identical (42). Indeed, analogous to the
TGFbRI (44), the introduction of an aspartic acid for threo-
nine 206 in the GS box of the ActRIB leads to constitutive
activation of the kinase domain of this receptor (18)). This
supports the view that modifications in or near the GS box
are a general mechanism for activation of type I receptors of
the TGFb superfamily. Under normal conditions this occurs
through phosphorylation of the GS box by the type II re-
ceptor (17, 19). It is noteworthy that the introduction of
aspartate in the ActRIB results in complete activation of the
downstream pathway, because addition of activin to CHO
cells transfected with this mutant receptor does not lead to
a further increase in the 3TP luciferase response. A similar
mutation in TGFbRI resulted in only partial activation of the
downstream pathway (44). This suggests that the mechanism
or the threshold for activation of the type I receptor by the
type II receptor for activin is slightly different from that for
TGFb.
In conclusion, we showed that inhibin blocks activin sig-
naling in CHO cells at the level of the activin-receptor com-
plex, most likely through competition with activin at the
TABLE 1. Conservation of inhibin subunit aminoacid sequences
among different species
Inhibin a Inhibin bA Inhibin bB
Human 100 100 100
Porcine 84 100 99
Bovine 86 100 100
Rat 80 100 97
Mouse 78 100 97
Only the mature peptides were considered. For each inhibin sub-
unit the identity of the peptides is presented as a percentage of the
human sequence. The sequences used were obtained from the
SWISSPROT database (accession no. P05111, P08476, P09529;
P04087, P03970, P04088; P07994, P07995, P42917; P17490, P18331,
P17491; and Q04997, Q04998, Q04999; for human, porcine, bovine,
rat and mouse inhibin a, bA, and bB proteins, respectively).
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ActRIIs; the ActRIIBs are more sensitive. Whether inhibin
acts via a similar mechanism in other cell types or via a
separate inhibin receptor pathway remains to be determined.
In this regard it will be of particular interest to investigate
gonadotropic cells, because this cell type is very sensitive to
inhibin.
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Note Added in Proof
After submission of the manuscript, Lebrun and Vale showed evi-
dence confirming our hypothesis that overexpression of ActRIIs in K562
cells results in loss of sensitivity to inhibin (Lebrun, J. J., and W. W. Vale,
Activin and inhibin have antagonistic effects on ligand dependent
heterodimerization of the type I and type II activin receptors on human
erythroid differentiation, Mol Cell Biol, 17:1682–1691).
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